Pharmacokinetics and hemodialyzability of cefazolin in uremic patients.
Cefazolin may be used in azotemic patients at reduced dosage as suggested by others. Although hemodialysis removes some of the drug, therapeutic levels are maintained throughout dialysis after a single intravenous dose of 500 mg. Imperfect transport from blood to dialysate is related to protein binding but varies with the degree of azotemia. Small amounts of cefazolin may be administered to patients during dialysis by addition to dialysate.
D000328:Adult; D001692:Biological Transport; D002437:Cefazolin / Q000008:administration & dosage / Q000378:metabolism*; D002511:Cephalosporins / Q000378:metabolism*; D002986:Clinical Trials as Topic; D006801:Humans; D007263:Infusions, Parenteral; D007700:Kinetics; D008297:Male; D009846:Oliguria / Q000378:metabolism; D006435:Renal Dialysis; D014511:Uremia / Q000378:metabolism*
D002511:Cephalosporins; D002437:Cefazolin